EC proliferation is known to be transduced via VEGFR2 (Thomas, 1996) ; however, the exact role of VEGFR1 in the endometrium remains elusive. Although VEGFR1-mediated signalling is essential for vascularization, the higher binding affinity of VEGF for VEGFR1 only elicits a weak angiogenic signal that does not stimulate endothelial cell proliferation (Tasaki et al., 2010) . Furthermore, a non-vascular function for VEGF is proposed, as it is evident that the primary cellular source of VEGF in the uterus is the endometrial epithelium (Girling & Rogers, 2009 ). This observation supports a non-angiogenic role for VEGF in epithelial cell function, in addition to a pro-angiogenic paracrine mechanism for VEGF.
Several groups have examined VEGF and receptors in pregnant and non-pregnant uterus and found cycle-dependent expression in rabbits (Das, Chakraborty, Wang, Dey, & Hoffman, 1997) , pig (Winther, Ahmed, & Dantzer, 1999) , humans (Moller, Rasmussen, Lindblom, & Olovsson, 2001) , marmosets (Rowe, Wulff, & Fraser, 2003) and cows . Most studies show that oestradiol elicits its tropic effects on uterine angiogenesis by elevated expression and activity of VEGF. The first clear demonstration of oestradiol-induced effect of VEGF was from a study in the rat uterus, in which VEGF expression increased in response to oestradiol treatment (Cullinan-Bove & Koos, 1993) . Further studies by the same group went on to show the mechanism by which oestradiol stimulated VEGF expression resulting in increased microvascular permeability, in both isolated uterine epithelial cells and whole rat uteri (Kazi, Molitoris, & Koos, 2009) , (Kazi & Koos, 2007) . This effect was dependent on the simultaneous recruitment of hypoxiainducible factor and (HIF1) and oestrogen receptor alpha (ESR1) to the VEGFA gene promoter. Oestradiol enhanced VEGF in endometrial cells of mice (Shweiki, Itin, Neufeld, Gitay-Goren, & Keshet, 1993) , baboons (Niklaus, Aberdeen, Babischkin, Pepe, & Albrecht, 2003) , rhesus macaques (Nayak & Brenner, 2002) and humans (Mueller et al., 2000) , with less known about the response of VEGF to progesterone.
Far less is known about another key group of angiogenic growth regulators, the angiopoietins, in the endometrium. Both angiopoietin-1 and 2 (Ang-1/2) act via EC tyrosine kinase receptor and have opposing roles depending on the availability and interactions with VEGF (Hirchenhain et al., 2003) . Ang-1 is an agonist of TIE-2, which promotes interactions between endothelial cells and vascular smooth muscle cells, thereby contributing to the structural integrity and stabilization of a newly formed vascular network (Tsuzuki et al., 2013) . In contrast, Ang-2 is a natural antagonist of Ang-1 activity, competing at receptor binding sites, and its opposing functions are dependent on the presence of VEGF .
A small number of studies report on the angiopoietins in the endometrium and are limited to humans and mice Tsuzuki et al., 2013) . In human endometrium, immunoreactivity for Ang-1 was strongest in the glands with weaker staining in vascular smooth muscle cells (VSMCs) and ECs, throughout the menstrual cycle (Lash et al., 2012) , whereas Ang-2 increased in the mid-late secretory phase, compared with early secretory or follicular phase. In early pregnant mouse uterus, Ang-2 and 3 increased by day 5 in response to the ovarian steroids and were implicated in processes of decidualization .
No previous studies report on the expression of the angiopoietins in the cyclic ovine uterus, although one study showed increasing Ang-1 and 2 mRNA levels with the progression of early stage pregnancy in ovine maternal placenta (Grazul-Bilska et al., 2010) .
Another study investigated the effects of oestradiol regulation on several angiogenic growth factors in the endometrium, using an ovariectomized ewe model (Johnson, Grazul-Bilska, Redmer, & Reynolds, 2006 ). An increase in Ang-1, Ang-2 and TIE-2 mRNA expression in the endometrium was shown two hours post-oestradiol treatment. However, the importance of further study to clarify the expression and potential functions of the angiopoietins in the endometrium is essential.
Although a previous study reported on VEGF in ovine caruncular tissue during later pregnancy (Ruiz-Gonzalez et al., 2013) , there is a distinct lack of knowledge regarding the localization of VEGF family and the angiopoietins in the ovine endometrium and their regulation by steroid hormones. Thus, the aim of this study was to identify the temporal and spatial distribution patterns of VEGF and receptors and the angiopoietin family in the cyclic ovine endometrium, and in response to the ovarian steroids. Defining the expression pattern of these factors may provide further evidence to elucidate their physiological functions in the ovine uterus. To the best of our knowledge, this is the first study, which thoroughly explored and demonstrated VEGF/receptors and ANG1/2 and TIE-2 expression in both follicular and luteal phases of the oestrous cycle in the sheep model.
| MATERIAL S AND ME THODS

| Animals and tissue collection
All experimental procedures complied with regulations in the UK Animal (Scientific Procedures) Act, 1986 and were approved by the College's Ethics and Welfare Committee. Thirty proven fertile non-pregnant Welsh mountain ewes were used in this study, housed indoors and fed with hay and concentrate diet. Eight ewes were synchronized to a common day of oestrus using intravaginal Chronogest sponge (Intervet UK Ltd, Cambridge, UK) for 11 days and treated with 200 IU Pregnant Mare's Serum Gonadotrophin (PMSG; Intervet UK, Ltd, Buckinghamshire, UK) intramuscularly at the time of sponge removal. Having observed oestrous 24 hr following sponge removal, reproductive tracts were collected following euthanasia on days 9 for luteal phase (n = 5) and days 16 for follicular phase (n = 3). Blood samples were also collected from intact ewes at the time of killing. The remaining 22 animals were ovariectomized as previously described by (Raheem et al., 2013) . To remove the effect of endogenous gonadotrophins, luteinizing hormone and follicle stimulating hormone (LH and FSH), ewes were administered Buserelin acetate (gonadotrophin agonist; Suprefact, Aventis Pharma Ltd, Kent, UK) continuously by an osmotic pump (ALZET model, DURECT Corp, Cupertino, US), inserted subcutaneously in the forelimb at the time of ovariectomy. Buserelin was administered at 2 mg in 2 ml normal saline, and pumps were designed to secrete 2.5 μl/hr for 28 days. Following an 8-day recovery period, ovariectomized ewes were randomly assigned to receive daily intramuscular injections of one of the three treatments: i) 2 ml corn oil alone (also used as a vehicle for the hormonal treatments) for 10 days (ovariectomized; OVX; n = 6), ii) 25 mg progesterone for ten consecutive days (ovariectomized progesterone treated; OVX P; n = 8) or iii) 6 μg of 17β-oestradiol and 25 mg progesterone for 3 days followed by progesterone only (25 mg) for the remaining 7 days (ovariectomized estradiol + progesterone treated; OVX EP; n = 8). Blood samples were collected on alternate days following the first day of treatment; plasma was separated and stored at −20°C until hormone assays were performed for progesterone and oestradiol. Animals were euthanized 24 hr after the last hormone injection was administered and uterine horns were collected and several dissected transverse sections were fixed in 4% formalin (BDH, Poole, UK), stored in 70% ethanol and later embedded in paraffin wax blocks for immunohistochemistry.
| Measurements of oestradiol and progesterone levels in plasma
Progesterone plasma concentrations were analysed using ELISA kits (Ridgeway Science, Cirencester, UK) according to manufacturer's instructions using standards prepared in charcoal-stripped sheep plasma ranging from 0.5 to 20 ng/ml. Oestradiol plasma concentrations were determined by RIA as previously described (Robinson et al. 2002) . The intra-assay coefficient of variation was 3.2%. The inter-assay coefficient of variation was not calculated as all samples were analysed in a single assay. for 60 min at room temperature in a humidified chamber. Slides were rinsed prior to application of the avidin-biotin complex solution (Vectastain Universal Elite ABC kit, Vector Laboratories, Peterborough, UK) for 30 min at room temperature and detection of the primary antibody was visualized using 3, 3′-diaminobenzidine (DAB; Dako, Glostrup, Denmark) until colour development. Slides were counterstained in Harris Haematoxylin, dehydrated through an ascending series of alcohols and mounted using DPX, coverslipped and images were captured under an Olympus BX60 microscope (Olympus, Essex, UK).
| Immunohistochemistry
| Semi-quantitative analysis of immunostaining by H-score
The intensity of immunoreactivity for each antibody was assessed in cellular compartments within sections by a four-point semiquantitative scoring system as follows: negative (0), weak (1), moderate (2) and strong (3). The H-score manual method of visual analysis is a double-graded system in which the total sum of a graded average intensity score is multiplied by the percentage area expression. This obtains a score range from 0 to 300 by multiplying the intensity of the stains (score 0-3) and the percentage of area stained (0-100) as previously described (Ponglowhapan, Church, & Khalid, 2008) . Intensity of staining was considered separately in endometrial compartments in luminal epithelium, glands, stromal cells and vasculature. Percentage expression reflects the percentage area immuno-stained in each layer. The estimate was based on ten random fields per section from all the animals in each treatment group. The images were scored by two independent experienced assessors blinded to the corresponding experimental groups under scoring.
Data were analysed from a minimum of at least three animals per experimental group using GraphPad Prism one-way analysis of variance test with post hoc Tukey's test for multiple comparisons. p < .05 was considered to indicate a statistically significant difference.
| RE SULTS
| Plasma oestradiol and progesterone concentrations
At the time of uteri sample collection, plasma progesterone levels were higher in luteal phase animals (2.3 ± 0.49 ng/ml) in comparison with follicular phase ewes (below detection levels of the assay; <0.05 ng/ml). Progesterone was non-detectable in the OVX group, but significantly increased in both OVX P and OVX EP groups in response to progesterone (P 4 ) or estradiol + progesterone (E 2 +P 4 ) treatment, respectively ( Figure 1a ). Plasma oestradiol levels at sample collection from follicular phase ewes were 6.1 ± 1.69 pg/ml (Figure 1b) . In both OVX and OVX P ewes, oestradiol levels were below assay detection levels, whereas in OVX EP animals, oestradiol levels began a steady increase following injections administered daily for 3 consecutive days and continued to increase until day 10 of sample collection.
F I G U R E 1 Plasma concentrations of progesterone (a) and oestradiol (b) in ovariectomized ewes, treated with corn oil (vehicle) (OVX; n = 6), or progesterone (OVX P; n = 9) or oestradiol + progesterone (OVX EP; n = 8 Staining intensity: +++ = strong, ++ = medium, + = weak, -no staining.
| Effects of oestrous cycle on protein expression of VEGF in the ovine endometrium
Protein expression of VEGFA/R1/2, Ang-1/2 and TIE-2 was examined by immunohistochemistry and semi-quantified using H-score method. For each protein analysed, variation in the intensities of immunostaining detected in the cytoplasm of all cellular layers of the endometrium studied is summarized in Table 1 . VEGFA immunostaining was evident in all cellular layers examined in the endometrium in follicular and luteal phases (Figure 2a and b compared to OVX tissue. Combined OVXEP treatment produced the greatest up-regulation of VEGF in all cell types examined, above that of progesterone alone (p < .05; Figure 2c ).
| Effects of oestrous cycle on protein expression of VEGFR1 and 2 in the ovine endometrium
VEGFR1 exhibited a staining distribution pattern comparable to that of VEGFA. Cells of the luminal and glandular epithelium in the superficial endometrium were most strongly stained for VEGFR1 with no significant differences observed between follicular and luteal phases (Figure 3a and b) . In the vasculature, VEGFR1 stained stronger in follicular phase, evident in both endothelial cells and smooth muscle cells of capillaries, and arterioles, although there was no significant effect compared to luteal ewes (Figure 3a and b) . Overall staining indices for VEGFR2 were relatively lower than VEGFR1 in the endometrium, reflected by an approximate twofold higher H-score value for VEGFR1
than VEGFR2 in luminal and glandular epithelium and vascular cells (Figures 3g and 4g) . Cell-specific oestrus cycle-dependent differences in VEGFR2 expression were detected. In luteal phase, VEGFR2 was significantly higher in luminal epithelium compared to follicular phase, but not in the glands and stroma (p < .05; Figure 4a and b). In the vasculature, VEGFR2 was predominantly localized to the endothelial cells of blood vessels, with significantly stronger levels in the follicular phase (p < .05). Only a small number of cells in the stromal compartment stained positively for VEGFR2 from follicular and luteal animals.
| Effects of ovarian steroids on protein expression of VEGFR1 and 2 in the ovine endometrium
Treatment with the ovarian steroids (OVXP/EP) induced a significant increase in both VEGFR1 and VEGFR2 compared to OVX ewes in all epithelial and vascular cells but not in the stroma (Figures 3h and 4h ).
The effects of combined OVXEP treatment induced the strongest F I G U R E 3 Immunohistochemical localization and quantification of VEGFR1 in ovine endometrium. VEGFR1 in the follicular and luteal phases (a, b) of the oestrous cycle, and ovariectomized ewes treated with oestradiol and progesterone (OVXEP; c), progesterone (OVXP; d) or vehicle (OVX; e). Immunostaining with isotype antibody for negative control (f). VEGFR1 is visualized as brown staining (DAB) and nuclei are counterstained with haematoxylin. H-score values represent mean ± SEM (g, h). *significance (p < .05; n = 3). LE, luminal epithelium; GE, glandular epithelium; BV, blood vessel; ST, stroma. Scalebar: 50 μm 
| Effects of oestrous cycle on protein expression of angiopoietins in the ovine endometrium
Ang-1 and Ang-2 proteins were both expressed in a cycle-dependent manner and were detected in all cellular layers examined at varying intensities (Figures 5a, b and 6a, b) . In the blood vessels, Ang-1 is strongly evident in the supportive smooth muscle cells and in endothelial cells. Ang-1 is also detected in non-vascular luminal and glandular epithelium and in stroma. Ang-1 immunostaining was significantly reduced in follicular phase compared to luteal phase in epithelial cells and blood vessels. In luteal phase, Ang-1 is significantly increased in luminal epithelia, superficial glands and the vasculature, but not stroma (p < .05; Figure 5b ). Ang-2 protein exhibited a similar spatial distribution in uterine sections to Ang-1 (Figure 6a ). Ang-2 protein was detected in the luminal epithelium and stained stronger in glands of the superficial endometrium. Ang-2 was strongly evident in smooth muscle cells of the vasculature and in endothelial cells.
Immunostaining for Ang-2 was consistently higher in luteal phase animals in all cells examined except the stroma (p < .05; Figure 6b ).
| Effects of ovarian steroids on protein expression of the angiopoietins in the ovine endometrium
Both ANG1 and ANG2 proteins exhibited an increase in response to steroid treatments compared to OVX tissue (Figures 5 and 6 ). Overall, Ang-1 and 2 were distinct and significantly higher (p < .05) in all three cellular layers, although less elevated in the stroma, in response to progesterone treatment (Figures 5d and 6d) . Ang-1 and Ang-2 immunostaining was weak in response to combined OVXEP treatment and did not induce a significant effect in comparison with OVX tissues, reflected by H-score values approximately fourfold lower than for progesterone alone (Figures 5c and   6c ). TIE-2 protein was strongly associated with blood vessels in both follicular and luteal phases, with strong staining localized to both endothelial and smooth muscle cells of capillaries, arterioles and venules (Figure 7a and b) . TIE-2 immunoreactivity was highly detectable in the superficial glands, in follicular phase and most significantly in luteal phase. TIE-2 staining was undetectable in cells of the luminal epithelium in the luteal phase (Figure 7b) , and almost at undetectable levels in follicular phase (Figure 7a ). TIE-2 was up-regulated in response to both progesterone and combined oestradiol and progesterone treatments, in cells of the vasculature (p < .0001) and in the superficial glands (p < .0001).
| D ISCUSS I ON
In the present study, VEGFA protein and receptors were demonstrated by immunohistochemistry in the ovine endometrium, which have cycle-dependent variations in specific cell types and in response to the ovarian steroids. The main findings of our study demonstrated that epithelial, stromal and vascular cells produce VEGFA, and immunoreactivity in the vasculature was highest in the follicular phase. VEGF receptors were expressed by ECs of blood vessels, and specifically VEGFR2 vascular expression was highest in the follicular phase. VEGFR1 and VEGFR2 immunostaining was also present in the epithelial and stromal cells of the superficial endometrium. The distinct period of elevated VEGFA vascular expression in the follicular phase is in accordance with findings of (Punyadeera et al., 2006) who demonstrated increased VEGF expression in early proliferative human endometrium, and (Maas et al., 2001 ) who observed that early proliferative phase endometrium has higher angiogenic activity than late proliferative phase. The present study also described that in our ovariectomized model, the influence of oestradiol and progesterone induced high In accordance with previous studies in primates (Rowe et al., 2003) , cattle ( including VEGFA (Gabler, Einspanier, Schams, & Einspanier, 1999) .
In this study, the marked increase in VEGFA expression induced in epithelial cells by combined oestradiol and progesterone treatment suggests oestradiol regulation of VEGFA in these cell types, which may act to promote endometrial growth. Although no significant differences in VEGFA expression were observed across cycle phases in epithelial cells, a trend towards stronger staining in both glandular and luminal epithelial cells in mid-luteal phase was notable. In bovine uterus reported a stronger VEGF signal in luminal and glandular epithelium in luteal phase, but no significant differences were detected in stromal or smooth muscle cells. (Tasaki et al., 2010) showed that VEGF mRNA was highest at oestrus and VEGF protein peaked at early luteal phase in bovine endometrium.
The significance of VEGF in these cells types at this time may be required in stimulating the increase in secretory activity of epithelial cells during the luteal phase. Immunostaining with isotype antibody for negative control (f). TIE-2 is visualized as brown staining (DAB) and nuclei are counterstained with haematoxylin. H-score values represent mean ± SEM (g, h). Significance (*p < .05, ***p < .0001; n = 3). LE, luminal epithelium; GE, glandular epithelium; BV, blood vessel; ST, stroma. Scalebar: 50 μm
promoting associations between vascular cell types, to maintain blood vessel stability (Woolf, Gnudi, & Long, 2009 (Woolf et al., 2009 ).
Similarly, Ang-2 peaked in the luteal phase and was stimulated in response to progesterone.
Ang-2 antagonizes Ang-1 binding to TIE-2 and does not induce signal transduction. In doing so, Ang-2 can disrupt the associations between endothelial cells and peri-vascular support cells, to promote apoptosis and vessel regression (Woolf et al. 2009 ). Such processes may be advantageous during early gestation when placentation requires remodelling of an existing vascular network and formation of new branching vessels (Kappou et al., 2014) . Pro-angiogenic effects of Ang-2 are thought to be dependent on available local VEGF expression. It has been indicated that Ang-2 may promote the accessibility of ECs to VEGF, thereby promoting neovascularization.
Notably, a previous study in an OVX-ewe model reported that oestradiol-induced up-regulation of Ang-1/2 and TIE-2 occurred at 2 hr post-treatment (Johnson et al., 2006) . In fact, this response time was shorter than the oestradiol-induced up-regulation of VEGF, observed at 4 hr. In the present study, the effects of oestradiol were also stimulatory on angiopoietin expression; however, progesterone alone exhibited a greater response. Of interest would be to compare progesterone treatment in the aforementioned groups OVX-ovine model. However, differences in results between studies may be due to analysis at the protein level, in the present study, and at the mRNA level in the previous study.
Although no staining was evident in the luminal epithelium or stromal cells, TIE-2 was unexpectedly evident in glandular epithelium. Analysis of these results should be approached with some degree of caution, given that TIE-2 is an endothelial specific marker.
Possibly, there is a lack of specificity of the polyclonal antibody used, which could prove a limitation of this study. However, there is some previous evidence of non-vascular TIE-2 expression in epithelial cells and a distinct population of monocytes (Coffelt et al., 2010) . Future endometrium-specific studies of TIE-2 expression are required to discern these possibilities.
It is noteworthy to highlight the limitations of this study, in which antibodies with higher specificity may have been selected, and a more state of the art software analysis could have greater benefit.
However, it is also critical to highlight that there is very limited evidence for angiogenic factors in the sheep. Although many other species have been studied in this area, this study provides novel data, which is no doubt crucial, and may highlight species-specific differences in implantation and placentation, that would subsequently be reflected in differences in angiogenic factor expression. Studies in ruminant species of economic relevance like sheep are critical, as evidence is limited on VEGF in cyclic ovine endometrium but has only been demonstrated in pregnant uterus (Grazul-Bilska et al., 2010) .
Early embryonic loss is a limiting factor which compromises reproduction, reflected in the fact that high fertilization rates (70%-80%) do not necessarily equate to similar pregnancy rates (Bridges, Day, Geary, & Cruppe, 2013) . Deficient development and/or function of the vasculature may be a contributing factor to such early pregnancy loss.
In conclusion, this study provides evidence that VEGF and receptors VEGFR1/2 are expressed by uterine epithelial, vascular and stromal cells in the ovine endometrium, in a cycle-dependent manner, predominantly induced by oestradiol. The angiopoietin system is dominant in the luteal phase, and regulated by progesterone may be involved in processes of vessel integrity and stabilization of a newly formed maternal vascular system.
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